home / stock / acst / acst news


ACST News and Press, Acasti Pharma Inc. From 09/21/22

Stock Information

Company Name: Acasti Pharma Inc.
Stock Symbol: ACST
Market: NASDAQ
Website: acastipharma.com

Menu

ACST ACST Quote ACST Short ACST News ACST Articles ACST Message Board
Get ACST Alerts

News, Short Squeeze, Breakout and More Instantly...

ACST - Acasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - September 21, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. CEO of the Company, Jan D'Alvise, join...

ACST - Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference

LAVAL, Québec, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, announ...

ACST - Acasti begins dosing of GTX-102 for neurodegenerative disorder; appoints chief commercial officer

Acasti Pharma ( NASDAQ: ACST ) said it began dosing in a phase 1 bridging study of oral betamethasone spray GTX-102 in healthy children. GTX-102 is a proprietary, concentrated oral spray of betamethasone intended to improve the neurological symptoms of Ataxia Telangiecta...

ACST - Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company's Drug Candidate for the Treatment of Ataxia Telangiectasia

LAVAL, Québec, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the comparative bioavailability, ph...

ACST - Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

LAVAL, Québec, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today ...

ACST - Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q1 2023 Results - Earnings Call Transcript

Acasti Pharma Inc. (ACST) Q1 2023 Earnings Conference Call August 11, 2022 01:00 PM ET Company Participants Robert Blum - Lytham Partners, Investor Relations Jan D'Alvise - President & Chief Executive Officer Brian Ford - Chief Financial Officer Pierre Le...

ACST - Acasti Pharma GAAP EPS of -$0.10

Acasti Pharma press release ( NASDAQ: ACST ): Q1 GAAP EPS of -$0.10. Cash, cash equivalents and short-term investments of $38.4M. Given certain cost savings and overall efficiencies implemented across the organization, management believes that it now has sufficient cap...

ACST - Acasti Pharma Reports First Quarter 2023 Operational Results

LAVAL, Québec, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today a...

ACST - Notable earnings before Thursday's open

Major earnings expected before the bell on Thursday include: Arrival ( ARVL ) Brookfield Asset Management ( BAM ) Cardinal Health ( CAH ) Hanesbrands ( HBI ) Himax Technologies ( HIMX ) For further details see: Notable earnings before Thur...

ACST - Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022

Call to be held on Thursday, August 11th at 1:00 PM Eastern Time LAVAL, Quebec, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), today announced that it will host a conference call at 1:00 ...

Previous 10 Next 10